

ETH 2006, Zurich, CH

Experimental Studies on the Pro-thrombotic Effect of Inhaled Particles

Peter HOET

Unit of Lung Toxicology

Occupational & Environmental Medicine

K.U.Leuven, Belgium

peter.hoet@med.kuleuven.be

Respiratory effects of particles

Episodes of increased PM₁₀ cause increase in **respiratory morbidity** such as:

- Respiratory symptoms
- Decrease in lung function
- Exacerbations of asthma in adults and children
- Hospitalization for bronchitis and pneumonia

Cardiovascular effects of particle exposure

- epidemiology & “clinical” studies:
 - increased particulate pollution associated with:
 - Heart rate variability \downarrow , arrhythmias without hypoxia or respiratory distress
 - Plasma viscosity \uparrow , C reactive protein \uparrow , fibrinogen \uparrow , factor VII \uparrow
 - PMN \uparrow , platelets \uparrow , mast cells \uparrow , endothelial adhesion molecules \uparrow

Effects of particles exposure

Particles are significant contributor to morbidity and mortality


not only with regard to the respiratory tract,

but also the cardiovascular system

Mechanisms?



- experimental toxicology:
 - which constituents of the particles?
 - by what mechanisms?
- “biological plausibility”?

Brook RD *et al.* Air pollution and cardiovascular disease. A statement for health-care professionals from the expert panel on population and prevention science of the American Heart Association. *Circulation* 2004 (June 1); 109: 2655-71



Translocation: Radioactivity in blood


Inhalation of ^{99m}Tc -carbon particles (“Technegas”)



Controversy going on ...

- Geiser M et al. Ultrafine Particles Cross Cellular Membranes by Nonphagocytic Mechanisms in Lungs and in Cultured Cells *Environ Health Perspect* 113:1555–1560 (2005).
- Mills et al., Do inhaled carbon nanoparticles translocate directly into the circulation in man? *Am J Respir Crit Care Med* Articles in Press. Dec 9, 2005.

Brook RD *et al.* Air pollution and cardiovascular disease. A statement for health-care professionals from the expert panel on population and prevention science of the American Heart Association. *Circulation* 2004 (June 1); 109: 2655-71



Methods


Pulmonary inflammation

- DEP 5 - 500 $\mu\text{g}/\text{animal}$ or vehicle were i.t. instilled to hamster

1 hour

Bronchoalveolar lavage (BAL)

Saline



- Cells
- Proteins
- Histamine


Nemmar A. *et al.* Am J Respir Crit Care Med, 2002, 166, 998–1004

Nemmar A. *et al.* Circulation, 2003, 107, 1202-8


Results

Pulmonary inflammation (BAL)


Neutrophils



Proteins



Histamine



Thrombus Formation: Methods

5-5,000 $\mu\text{g}/\text{kg}$ i.v.

Jugular vein

0.5-5 mg/kg i.t.

Light source


Femoral vein

Thrombus

Transilluminator

Femoral vein

1. inject particles (or vehicle) i.v. or i.t.
2. 10 min later, inject Rose Bengal i.v.
3. 2 min transillumination (540 nm)
→ oxidative damage to endothelium
4. follow thrombus formation during 40 min
5. BAL (protein, LDH, cells) (*only after i.t.*)






Thrombus Formation: Materials & animals

- Polystyrene microspheres of 60 nm \emptyset
 - unmodified: neutral
 - carboxylate-modified: **negatively** charged
 - amine-modified: **positively** chargedsuspended in NaCl 0.9%
sonicated + vortexed immediately before administration
- Hamsters (100-150g), anaesthetized
n=3-4 per day, including 1 vehicle control


Thrombus Formation: Results

particles i.v.




Thrombus Formation: Results

particles i.t.




Silva VM, Corson N, Elder A, Oberdörster G. The rat ear vein model for investigating in vivo thrombogenicity of ultrafine particles (UFP). *Tox Sci*, 2005, 85, 983-9



Thrombus Inducing Time (TIT)



Aminated (+) Polystyrene UFPs (60 nm) injected iv or it 10-15 min after baseline (without Rose Bengal)

Thrombus Formation: Results



Thrombus Formation: Results

Peripheral arterial thrombosis



Thrombus Formation & Pulmonary Inflammation

Summary & conclusion

- Within 1 hour after their deposition in the lungs, (Polystyrene - DEP)
 - cause pulmonary inflammation
 - aggravate thrombosis

Additional questions

The kinetics of

- Pulmonary inflammation?
- Platelet function following exposure to particles?
- And how is thrombogenicity affected by pulmonary inflammation?

Methods

- Time effects: 1, 6 and 24h after DEP exposure
- Hamsters i.t. instilled with DEP
 - (50 µg/animal, n= 4-6)
- Endpoints assessed
 - Lung inflammation (PMN)
 - Thrombosis (+ Platelet activation)
 - **Histamine** concentrations in
BAL & in plasma

Methods

Platelet activation

Platelet function analysis
PFA-100[®]

800 μ l blood

- 40 mbar

Opening: \varnothing 150 μ m

Membrane coated with
collagen & epinephrine


von Willebrand Factor

FLOW

capillary 200 μ m


red blood cells

platelet



Methods

Platelet activation



Methods

Platelet function analysis

ex vivo

i.t. DEP (50 $\mu\text{g}/\text{animal}$) or saline

blood

blood collection

5, 15, 30 and 60 min

in vitro

DEP (0.1 - 5 μg)


+

1ml hamster

5 min incubation


Time effect of i.t. DEP

Thrombosis *in vivo*




Time effect of i.t. DEP

Platelet aggregation (PFA) *ex vivo*




Time effect of i.t. DEP

Platelet aggregation (PFA) *ex vivo*




Time effect of i.t. DEP

Pulmonary inflammation (BAL)




Time effect of i.t. DEP *in vivo*

Histamine measurements



Time effect of i.t. DEP *in vivo*

Histamine measurements



Time effect of i.t. DEP:

Summary

- I.t. instillation of DEP leads to a significant **prothrombotic** effect and **lung inflammation**, which persist up to 24 h.
- **Histamine** concentrations were increased in **BAL** at **all time points** but in **plasma**, **histamine** levels were only increased at **6 and 24h** and **not at 1h.**
- Effects of i.t. DEP on pulmonary inflammation and peripheral thrombosis (at 6 & 24 h) can be blocked by pretreatment with **diphenhydramine**, **dexamethasone** or **cromoglycate**


Interpretation

- We conclude that:
 - Pulmonary inflammation and peripheral thrombosis are correlated at 6 and 24h.
 - At 1h, the prothrombotic effect does not appear to result from pulmonary inflammation.



This is compatible with direct platelet activation by “particles” (or its constituents) having penetrated into the circulation

Brook RD *et al.* Air pollution and cardiovascular disease. A statement for health-care professionals from the expert panel on population and prevention science of the American Heart Association. *Circulation* 2004 (June 1); 109: 2655-71



Acknowledgements

K.U.Leuven, Belgium

– *Laboratory of Pneumology*

(Unit of Lung Toxicology)

B. Nemery

A. Nemmar

P. Hoet

J. Geys

– *Centre for Molecular and
Vascular Biology*

M.F. Hoylaerts

J. Vermylen

MRC, Leicester, U.K.

– *Toxicology Unit*

D. Dinsdale

Sponsors:

- FWO


- OT-KULeuven

Thank you for your
attention

Some recent data - unpublished


- Pro-thrombotic effect of carbon nanotubes (24 hr after dosing)
- Thrombotic effect of quantum dots (iv dosing)

Pro-thrombotic effect of carbon nanotubes




Mouse dosed iv with:

- Biocompatible carboxylated quantum dots
- 4 $\mu\text{g}/\text{animal}$



Non stained - fluorescence

Hematoxylin



Mechanisms of particle-induced lung inflammation and vascular thrombosis?




Nemmar *et al.* Am. J. Respir. Crit. Care Med. 2005; 171:872-89

Silica particles

Pulmonary inflammation

24 h

Peripheral thrombosis



Silica particles

– Strategy of depletion:

- I.t. clodronate liposomes: pulmonary macrophages (↓ 70 %)
- I.p. cyclophosphamide: PMN depletion (↓ 80 %)

<u>Pretreatment</u>	<u>Lung inflammation</u>	<u>peripheral thrombosis</u>
Clodronate	inhibition	inhibition
Cyclophosphamide	inhibition	inhibition


– Additional results:

- Elastase increases in BAL and plasma (+ partial but significant reduction of thrombosis after i.t. pretreatment with MeOSuc-AAPV-CMK, a specific neutrophil elastase inhibitor)






- Critical role of pulmonary macrophage-neutrophil cross-talk releasing neutrophil elastase into the blood circulation.
- Elastase, triggering activation of circulating platelets, may then predispose platelets to initiate thrombotic events on mildly damaged vasculature.

Translocation: Radioactivity in blood






intratracheal instillation of ^{99m}Tc -albumin nanocolloid particles (80 nm) in hamsters 0




Nemmar *et al.* Am. J. Respir. Crit. Care Med. 2001;164:1665-8.




Mills et al



Nemmar et al





from Brook *et al.* Circulation 2004, 109, 2655-71)